ChartMill assigns a Buy % Consensus number of 84% to PALI. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-01-09 | B. Riley Securities | Initiate | Buy |
| 2025-12-30 | Clear Street | Initiate | Buy |
| 2025-12-29 | Piper Sandler | Initiate | Overweight |
| 2025-05-13 | Brookline Capital | Maintains | Buy -> Buy |
| 2024-11-20 | Brookline Capital | Initiate | Buy |
| 2024-11-13 | Maxim Group | Maintains | Buy -> Buy |
| 2024-05-01 | Maxim Group | Reiterate | Buy -> Buy |
| 2024-04-16 | Maxim Group | Maintains | Buy -> Buy |
| 2023-11-17 | Maxim Group | Upgrade | Hold -> Buy |
| 2023-05-16 | Ladenburg Thalmann | Maintains | Buy -> Buy |
| 2023-03-30 | Maxim Group | Upgrade | Hold -> Buy |
| 2022-08-19 | Maxim Group | Downgrade | Buy -> Hold |
| 2022-02-02 | Ladenburg Thalmann | Initiate | Buy |
| 2021-08-31 | Maxim Group | Initiate | Buy |
10 analysts have analysed PALI and the average price target is 13.43 USD. This implies a price increase of 734.16% is expected in the next year compared to the current price of 1.61.
The consensus rating for PALISADE BIO INC (PALI) is 84 / 100 . This indicates that analysts generally have a positive outlook on the stock.